Kelly Jason R's Form 4 filing
Ginkgo Bioworks Holdings, Inc. (DNA) · filed Dec 23, 2022
- Accession no.
- 0001127602-22-028247
- Filed
- Dec 23, 2022
- Trade date
- Dec 21-22, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $676.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kelly Jason RCIK 0001845677 | Director, Officer (See remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 21, 2022 | Class A Common Stock | SSaleDisposed | −193,211 | $1.70 | −$328,458.7 | 18,200,389 | Direct | |
| Dec 22, 2022 | Class A Common Stock | SSaleDisposed | −209,385 | $1.66 | −$347,579.1 | 17,991,004 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
CEO & Founder